Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
American Journal of Cardiovascular Drugs
Erschienen in: American Journal of Cardiovascular Drugs 6/2008

01.11.2008 | Review Article

Peripheral Arterial Disease in the Elderly

Recognition and Management

verfasst von: Dr Herbert Aronow

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Peripheral arterial disease (PAD) is a common but frequently overlooked vascular disease, often affecting the lower extremities. The prevalence of PAD increases exponentially with age, and this is of particular concern among the elderly population because this condition frequently signals disease in other vascular beds, including the coronary arteries and/or cerebral vasculature. In addition to the increased risk of cardiovascular disease and stroke, patients with PAD may also experience functional impairment and decreased quality of life.
The ankle-brachial index is the most effective and widely used screening tool for detecting PAD and should be performed when PAD is suspected, based on the medical history or physical examination. Current treatment guidelines recommend risk factor modification, including exercise therapy and smoking cessation interventions, combined with pharmacologic measures for secondary prevention and management of symptoms of PAD. Antiplatelet therapy is an integral component of global cardiovascular risk reduction strategies in patients with PAD.
Current guidelines provide a significant opportunity for practitioners to detect and treat patients with PAD in a timely and effective manner, thereby improving the overall mortality, morbidity, and quality of life associated with this disease.
Literatur
1.
Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006 Feb; 295(5): 547–53.PubMedCrossRef
2.
Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 2004 Aug; 110(6): 738–43.PubMedCrossRef
3.
Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985 Mar; 71(3): 510–5.PubMedCrossRef
4.
Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001 Sep; 286(11): 1317–24.PubMedCrossRef
5.
McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001 Oct; 286(13): 1599–606.PubMedCrossRef
6.
Hooi JD, Kester AD, Stoffers HE, et al. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol 2001 Apr; 153(7): 666–72.PubMedCrossRef
7.
Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006 Mar; 113(11): e463–654.PubMedCrossRef
8.
Meijer WT, Grobbee DE, Hunink MG, et al. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med 2000 Oct 23; 160(19): 2934–8.
9.
Doubeni CA, Yood RA, Emani S, et al. Identifying unrecognized peripheral arterial disease among asymptomatic patients in the primary care setting. Angiology 2006 Mar–Apr; 57(2): 171–80.
10.
Meijer WT, Hoes AW, Rutgers D, et al. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol 1998 Feb; 18(2): 185–92.PubMedCrossRef
11.
Levy PJ, Hornung CA, Haynes JL, et al. Lower extremity ischemia in adults younger than forty years of age: a community-wide survey of premature atherosclerotic arterial disease. J Vasc Surg 1994 May; 19(5): 873–81.PubMedCrossRef
12.
Harris LM, Peer R, Curl GR, et al. Long-term follow-up of patients with early atherosclerosis. J Vasc Surg 1996 Apr; 23(4): 576–80; discussion 81.PubMedCrossRef
13.
Valentine RJ, Myers SI, Inman MH, et al. Late outcome of amputees with premature atherosclerosis. Surgery 1996 May; 119(5): 487–93.PubMedCrossRef
14.
Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006 Jan; 295(2): 180–9.PubMedCrossRef
15.
Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999 Oct; 47(10): 1255–6.PubMed
16.
Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007 Mar; 297(11): 1197–206.PubMedCrossRef
17.
Wong SY, Woo J, Hong AW, et al. Clinically relevant depressive symptoms and peripheral arterial disease in elderly men and women: results from a large cohort study in Southern China. J Psychosom Res 2007 Nov; 63(5): 471–6.PubMedCrossRef
18.
Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998 Feb; 97(5): 425–8.PubMedCrossRef
19.
O’Hare AM, Newman AB, Katz R, et al. Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med 2005 Dec; 165(22): 2666–70.PubMedCrossRef
20.
O’Hare AM, Vittinghoff E, Hsia J, et al. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/ Progestin Replacement Study (HERS). J Am Soc Nephrol 2004 Apr; 15(4): 1046–51.PubMedCrossRef
21.
Eason SL, Petersen NJ, Suarez-Almazor M, et al. Diabetes mellitus, smoking, and the risk for asymptomatic peripheral arterial disease: whom should we screen? J Am Board Fam Pract 2005 Sep-Oct; 18(5): 355–61.
22.
Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000 Jan; 31(1 Pt 2): S1–S296.PubMed
23.
Novo S, Avellone G, Di Garbo V, et al. Prevalence of risk factors in patients with peripheral arterial disease: a clinical and epidemiological evaluation. Int Angiol 1992Jul–Sep; 11(3): 218–29.PubMed
24.
Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001 May 16; 285(19): 2481–5.
25.
Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992 Feb; 326(6): 381–6.PubMedCrossRef
26.
McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med 1999 Feb; 159(4): 387–92.PubMedCrossRef
27.
Aronow WS, Ahn C. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002 Oct; 90(7): 789–91.PubMedCrossRef
28.
Fleg JL, Lakatta EG. Role of muscle loss in the age-associated reduction in VO2 max. J Appl Physiol 1988 Sep; 65(3): 1147–51.PubMed
29.
Conley KE, Esselman PC, Jubrias SA, et al. Ageing, muscle properties and maximal O(2) uptake rate in humans. J Physiol 2000 Jul; 526 Pt 1: 211–7.PubMedCrossRef
30.
Coggan AR, Spina RJ, King DS, et al. Histochemical and enzymatic comparison of the gastrocnemius muscle of young and elderly men and women. J Gerontol 1992 May; 47(3): B71–6.PubMedCrossRef
31.
Dinenno FA, Tanaka H, Stauffer BL, et al. Reductions in basal limb blood flow and vascular conductance with human ageing: role for augmented alpha-adrenergic vasoconstriction. J Physiol 2001 Nov; 536(Pt 3): 977–83.PubMedCrossRef
32.
Rice TW, Lumsden AB. Optimal medical management of peripheral arterial disease. Vasc Endovascular Surg 2006 Aug–Sep; 40(4): 312–27.
33.
Khan NA, Rahim SA, Anand SS, et al. Does the clinical examination predict lower extremity peripheral arterial disease? JAMA 2006 Feb; 295(5): 536–46.PubMedCrossRef
34.
Marcon G, Barbato O, Scevola M, et al. Unnecessary arterial Doppler examination of the legs: clinical decision rules may help? Qual Assur Health Care 1991; 3: 115–22.PubMedCrossRef
35.
Butler JV, Mulkerrin EC, O’Keeffe ST. Nocturnal leg cramps in older people. Postgrad Med J 2002 Oct; 78(924): 596–8.PubMedCrossRef
36.
Hooi JD, Stoffers HE, Kester AD, et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease. The Limburg PAOD Study. Peripheral Arterial Occlusive Disease. Scand J Prim Health Care 1998 Sep; 16(3): 177–82.PubMedCrossRef
37.
Yao ST, Hobbs JT, Irvine WT. Ankle systolic pressure measurements in arterial disease affecting the lower extremities. Br J Surg 1969 Sep; 56(9): 676–9.PubMedCrossRef
38.
Fowkes FG. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol 1988 Jun; 17(2): 248–54.PubMedCrossRef
39.
Vogt MT, Cauley JA, Newman AB, et al. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993 Jul; 270(4): 465–9.PubMedCrossRef
40.
Fowkes FG, Low LP, Tuta S, et al. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J 2006 Aug; 27(15): 1861–7.PubMedCrossRef
41.
McDermott MM, Feinglass J, Slavensky R, et al. The ankle-brachial index as a predictor of survival in patients with peripheral vascular disease. J Gen Intern Med 1994 Aug; 9(8): 445–9.PubMedCrossRef
42.
Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg 1999 Jun; 12(2): 142–7.PubMed
43.
Papamichael CM, Lekakis JP, Stamatelopoulos KS, et al. Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease. Am J Cardiol 2000 Sep; 86(6): 615–8.PubMedCrossRef
44.
Ogren M, Hedblad B, Isacsson SO, et al. Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis. Lancet 1993 Nov; 342(8880): 1138–41.PubMedCrossRef
45.
Kindermann M, Adam O, Werner N, et al. Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol 2007 Nov; 96(11): 767–86.PubMedCrossRef
46.
Rehring TF, Sandhoff BG, Stolcpart RS, et al. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005 May; 41(5): 816–22.PubMedCrossRef
47.
Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007 Jan; 45 Suppl. S: S5–67.PubMedCrossRef
48.
Ness J, Aronow WS, Newkirk E, et al. Prevalence of symptomatic peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of peripheral arterial disease in older persons seen in a university general medicine clinic. J Gerontol A Biol Sci Med Sci 2005 Feb; 60(2): 255–7.PubMedCrossRef
49.
Navas-Acien A, Selvin E, Sharrett AR, et al. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation 2004 Jun; 109(25): 3196–201.PubMedCrossRef
50.
Powell JT, Edwards RJ, Worrell PC, et al. Risk factors associated with the development of peripheral arterial disease in smokers: a case-control study. Atherosclerosis 1997 Feb; 129(1): 41–8.PubMedCrossRef
51.
Fowler B, Jamrozik K, Norman P, et al. Prevalence of peripheral arterial disease: persistence of excess risk in former smokers. Aust N Z J Public Health 2002; 26(3): 219–24.PubMedCrossRef
52.
Hirsch AT, Treat-Jacobson D, Lando HA, et al. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 1997; 2(3): 243–51.PubMed
53.
Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ 2003 Mar; 326(7389): 584–8.PubMedCrossRef
54.
Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999 Mar; 340(9): 685–91.PubMedCrossRef
55.
Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006 Jul; 296(1): 47–55.PubMedCrossRef
56.
Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006 Jul; 296(1): 56–63.PubMedCrossRef
57.
Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006 Jul; 296(1): 64–71.PubMedCrossRef
58.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul; 360(9326): 7–22.CrossRef
59.
Antithrombotic Trialists’Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan; 324(7329): 71–86.CrossRef
60.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 Nov; 348(9038): 1329–39.CrossRef
61.
Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998 Feb; 27(2): 267–74; discussion 74–5.PubMedCrossRef
62.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan; 342(3): 145–53.PubMedCrossRef
63.
Whitson HE, Heflin MT, Burchett BM. Patterns and predictors of smoking cessation in an elderly cohort. J Am Geriatr Soc 2006 Mar; 54(3): 466–71.PubMedCrossRef
64.
Chaaya M, Mehio-Sibai A, El-Chemaly S. Smoking patterns and predictors of smoking cessation in elderly populations in Lebanon. Int J Tuberc Lung Dis 2006 Aug; 10(8): 917–23.PubMed
65.
Husten CG, Shelton DM, Chrismon JH, et al. Cigarette smoking and smoking cessation among older adults: United States, 1965–94. Tob Control 1997 Autumn; 6(3): 175–80.PubMedCrossRef
66.
Izquierdo-Porrera AM, Gardner AW, Powell CC, et al. Effects of exercise rehabilitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease. J Vasc Surg 2000 Apr; 31(4): 670–7.PubMedCrossRef
67.
Miller ME, Rejeski WJ, Reboussin BA, et al. Physical activity, functional limitations, and disability in older adults. J Am Geriatr Soc 2000 Oct; 48(10): 1264–72.PubMed
68.
Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis. JAMA 1995 Sep; 274(12): 975–80.PubMedCrossRef
69.
Woodburn KR, Murtagh A, Breslin P, et al. Insonation and impedance analysis in graft surveillance. Br J Surg 1995 Sep; 82(9): 1222–5.PubMedCrossRef
70.
Currie IC, Wilson YG, Baird RN, et al. Treatment of intermittent claudication: the impact on quality of life. Eur J Vasc Endovasc Surg 1995 Oct; 10(3): 356–61.PubMedCrossRef
71.
Bendermacher BL, Willigendael EM, Teijink JA, et al. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2006; (2): CD005263.PubMed
72.
Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999–2000 National Health and Nutrition Examination Survey. Diabetes Care 2004 Jul; 27(7): 1591–7.PubMedCrossRef
73.
Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001 Nov; 24(11): 1936–40.PubMedCrossRef
74.
American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003 Dec; 26(12): 3333–41.CrossRef
75.
Jude EB, Oyibo SO, Chalmers N, et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001 Aug; 24(8): 1433–7.PubMedCrossRef
76.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 Sep; 352(9131): 854–65.CrossRef
77.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug; 321(7258): 405–12.PubMedCrossRef
78.
79.
Schillinger M, Exner M, Mlekusch W, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004 May; 25(9): 742–8.PubMedCrossRef
80.
Mohler 3rd ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003 Sep; 108(12): 1481–6.PubMedCrossRef
81.
Buchwald H, Bourdages HR, Campos CT, et al. Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH). Surgery 1996 Oct; 120(4): 672–9.PubMedCrossRef
82.
Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998 Feb; 81(3): 333–5.PubMedCrossRef
83.
Aronow WS, Nayak D, Woodworth S, et al. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003 Sep; 92(6): 711–2.PubMedCrossRef
84.
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6): 1206–52.PubMedCrossRef
85.
Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001 Jun 1; 87(11): 1284–6.PubMedCrossRef
86.
Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med 1991 Sep; 151(9): 1769–76.PubMedCrossRef
87.
Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004 Jan; 25(1): 17–24.PubMedCrossRef
88.
Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991 Oct; 115(7): 513–9.PubMed
89.
Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 Apr; 354(16): 1706–17.PubMedCrossRef
90.
Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000 Nov; 109(7): 523–30.PubMedCrossRef
91.
Reed AB, Conte MS, Donaldson MC, et al. The impact of patient age and aortic size on the results of aortobifemoral bypass grafting. J Vasc Surg 2003 Jun; 37(6): 1219–25.PubMedCrossRef
92.
Green RM, Abbott WM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. J Vasc Surg 2000 Mar; 31(3): 417–25.PubMedCrossRef
93.
Conte MS, Bandyk DF, Clowes AW, et al. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg 2005 Sep; 42(3): 456–64; discussion 64–5.PubMedCrossRef
Metadaten
Titel
Peripheral Arterial Disease in the Elderly
Recognition and Management
verfasst von
Dr Herbert Aronow
Publikationsdatum
01.11.2008
Verlag
Springer International Publishing
Erschienen in
American Journal of Cardiovascular Drugs / Ausgabe 6/2008
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI
https://doi.org/10.2165/0129784-200808060-00002

Weitere Artikel der Ausgabe 6/2008

American Journal of Cardiovascular Drugs 6/2008 Zur Ausgabe

Review Article

Candidate Mechanisms for Regression of Coronary Atherosclerosis with High-Dose Statins

Original Research Article

Cost Effectiveness of Ezetimibe in Patients with Cardiovascular Disease and Statin Intolerance or Contraindications

Review Article

Statin Adverse Effects

Acknowledgments

Acknowledgment

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen